{
    "clinical_study": {
        "@rank": "82502", 
        "brief_summary": {
            "textblock": "The study purpose is to evaluate the clinical response to multidose administration of\n      anti-Tac monoclonal antibody conjugated with 10 mCi 90Y in patients with Tac-expressing\n      adult T-cell leukemia (ATL)."
        }, 
        "brief_title": "Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac", 
        "completion_date": "October 2000", 
        "condition": [
            "Leukemia, T-Cell", 
            "Lymphoma, T-Cell, Cutaneous"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, T-Cell", 
                "Leukemia-Lymphoma, Adult T-Cell", 
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Cutaneous"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study purpose is to evaluate the clinical response to multidose administration of\n      anti-Tac monoclonal antibody conjugated with 10 mCi 90Y in patients with Tac-expressing\n      adult T-cell leukemia (ATL).  This study represents an extension of phase I trial (Clinical\n      Project #90-C-0043, FDA IND #3469) which permitted the administration of 5 mCi, 10 mCi, and\n      15mCi 90Y-anti-Tac to patients with ATL.  We propose to administer 90Y-anti-Tac (10 mCi\n      doses) to patients with Tac-expressing ATL who are over 18 years of age and who fill the\n      patient eligibility criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n        Histologically confirmed adult T-cell leukemia/lymphoma (ATL) or cutaneous T-cell lymphoma\n        (CTCL).\n\n        Reactivity of at least 10% of peripheral blood, lymph node, or dermal malignant cells with\n        anti-Tac as determined by immunofluorescent staining or soluble IL-2 receptor level\n        greater than 1,500 U required.\n\n        All stages of Tac-expressing T-cell leukemia and lymphoma eligible except Stage I CTCL.\n\n        All forms of ATL eligible, including the \"smoldering\" type as well as aggressive disease.\n\n        No symptomatic CNS disease other than tropical spastic paraparesis.\n\n        Asymptomatic CNS disease with demonstrable malignant cells in the CSF allowed (such\n        patients receive CNS therapy, e.g., intrathecal methotrexate and/or CNS irradiation, as\n        appropriate).\n\n        PRIOR/CONCURRENT THERAPY:\n\n        Biologic Therapy: Not specified.\n\n        Chemotherapy:\n\n        CTCL must have failed initial chemotherapy.\n\n        ATL may or may not have had prior chemotherapy.\n\n        At least 4 weeks since prior cytotoxic chemotherapy.\n\n        Endocrine Therapy: Not specified.\n\n        Radiotherapy: At least 4 weeks since prior radiotherapy.\n\n        Surgery: Not specified.\n\n        PATIENT CHARACTERISTICS:\n\n        Age: 18 and over.\n\n        Performance status: Not specified.\n\n        Life expectancy: Greater than 1 month.\n\n        Hematopoietic: WBC at least 3,000, Platelets at least 75,000.\n\n        Hepatic: Not specified.\n\n        Renal: Not specified.\n\n        Other:\n\n        No pregnant women.\n\n        Negative pregnancy test required of fertile women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001249", 
            "org_study_id": "900043", 
            "secondary_id": "90-C-0043"
        }, 
        "intervention": {
            "intervention_name": "Yttrium-90 radiolabeled anti-Tac antibody", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Daclizumab"
            ]
        }, 
        "keyword": "Interleukin-2 Receptor", 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "2846094", 
                "citation": "Waldmann TA, Goldman CK, Bongiovanni KF, Sharrow SO, Davey MP, Cease KB, Greenberg SJ, Longo DL. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood. 1988 Nov;72(5):1805-16."
            }, 
            {
                "PMID": "2785435", 
                "citation": "Kozak RW, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghans RP, Gansow OA, Waldmann TA, Junghaus R. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res. 1989 May 15;49(10):2639-44."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001249"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1989", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1999"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}